A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples